Excellence in Single Domain Biotherapeutics
Isogenica develops therapeutic VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
Our VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.
Isogenica’s LlamdA® VHH synthetic libraries are displayed in phage or in the company’s proprietary CIS Display technology.
These are combined to provide a powerful discovery engine for single domain biotherapeutics.
News & Events
A collaboration with the University of Nottingham and Aston University Advances in computing and data science, such as machine learning (ML) and...
Isogenica visiting the team at the University of LeicesterImmunotherapy has transformed the cancer treatment landscape in recent years, harnessing...
Careers at Isogenica
A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.